PhenGene P2Y12 Test
CLOPIDOGREL is used widely to reduce the risk of recurrent heart attack and stroke*. However, around 1/3 of individuals do not sufficiently respond to the drug, leading to reduced protection from recurrent thrombotic events in these patients. One of the most prevalent reasons for reduced response to CLOPIDOGREL is inefficient metabolism of the drug into its active form due to genetic variability in liver enzymes.
PhenGene P2Y12 TestTM is the first dual test to identify at risk/sub optimally responsive patients to Clopidogrel for whom alternative treatment options can be used. The test combines specific functional assessment of platelet inhibition (target for Clopidogrel) and genetic test to determine the metabolic profile of the drug. PhenGene P2Y12 TestTM is offered in collaboration with Cellomatics Biosciences Ltd.
* CVDs are the number 1 cause of death globally. An estimated 17.5 million people died from CVDs in 2012, representing 31% of all global deaths. Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke. (World Health Organization, http://www.who.int/mediacentre/factsheets/fs317/en/)